Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

The Broad Institute, Inc.

Sema Kurtulus

Aviv Regev

Vijay K Kuchroo

Ana Carrizosa Anderson

Asaf Madi

The subject matter disclosed herein is generally directed to novel CD8tumor infiltrating lymphocyte (TIL) subtypes associated with response to immunotherapy treatment. Specifically, the subtypes are associated with checkpoint blockade therapy. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the subtypes. Also, disclosed herein are gene signatures and markers associated with the subtypes and use of said signatures and markers. Further disclosed are therapeutic methods of using said gene signatures and immune cell subtypes. Further disclosed are pharmaceutical compositions comprising populations of CD8TILs enriched for a specific subtype.

Growing community of inventors

Boston, MA, United States of America

Sema Kurtulus